Polarean Imaging PLC New System Order (1929B)
05 Junio 2019 - 1:01AM
UK Regulatory
TIDMPOLX
RNS Number : 1929B
Polarean Imaging PLC
05 June 2019
Polarean Imaging Plc
("Polarean" or the "Company")
New System Order
Polarean Imaging plc (AIM: POLX), the medical-imaging technology
company, with a proprietary drug-device combination product for the
magnetic resonance imaging (MRI) market, announces the Company has
received its latest research unit order for a 9820 Xenon Polariser
system from The Hospital for Sick Children ("SickKids") in Toronto
www.sickkids.ca.
SickKids is a major paediatric research and teaching hospital
and already has an earlier model Polarean polariser (which was
recently upgraded). This new unit will expand SickKids' ongoing
paediatric research programme using hyperpolarised gas imaging.
Their order was enabled by a grant from the Canada Foundation for
Innovation ("CFI") www.innovation.ca/about. Following receipt of
this order, the total number of the Company's polarisers that are
either installed or on order is 24.
Richard Hullihen, CEO of Polarean, said: "We are very happy to
extend our long-standing relationship with SickKids Hospital in
Toronto who work tirelessly on the paediatric applications of
hyperpolarised xenon imaging for this important patient
population."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood
(Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7879
741 001
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue generating, medical drug-device
combination companies operating in the high resolution medical
imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation and gas exchange regionally
in the smallest airways of the lungs, the tissue barrier between
the lung and the bloodstream and in the pulmonary vasculature.
Xenon gas exhibits solubility and signal properties that enable it
to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel diagnostic approach,
offering a non-invasive and radiation-free functional imaging
platform which is more accurate and less harmful to the patient
than current methods. The annual burden of pulmonary disease in the
US is estimated to be over US$150 billion.
The Group also develops and manufactures high performance MRI
radiofrequency (RF) coils which are a required component for
imaging (129) Xe in the MRI system. The development of these coils
by the Group facilitates the adoption of the Xenon technology by
providing application-specific RF coils which optimise the imaging
of (129) Xe in MRI equipment for use as a medical diagnostic as
well as a method of monitoring the efficacy of therapeutic
intervention.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGSGDLLBGBGCU
(END) Dow Jones Newswires
June 05, 2019 02:01 ET (06:01 GMT)
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
